Benefits
Negative for testosterone boosting
A human study evaluated daily treatment for 21 days with propolis and honey containing chrysin in healthy male volunteers. Result: NO alterations in urinary testosterone levels at days 7, 14, or 21 vs baseline or controls. The authors concluded that these foods at the doses usually taken as oral supplementation do not affect the equilibrium of testosterone in human males. This is a negative result for the most common marketing claim, and it is not the only one. Two randomized trials in men (20 young men over 8 weeks, and 55 men aged 30 to 59 over 28 days) gave 625 mg/day of chrysin inside an androstenedione stack specifically to block conversion of androgen to estrogen. In both, total testosterone was unchanged and estradiol rose, by 103 percent in the older group, so the chrysin did not do the one job it is sold to do. Strength gains over 8 weeks matched placebo. Chrysin was one ingredient among several in those products, so its separate effect cannot be isolated.
In vitro aromatase inhibition (no clinical translation)
Multiple in vitro studies show chrysin is among the more potent flavonoid aromatase inhibitors (IC50 values in micromolar range). In people the mechanism has failed every time it has been tested. Two randomized trials gave 625 mg/day of chrysin inside an androstenedione stack for exactly this purpose, to stop ingested androgen turning into estrogen: in 20 young men over 8 weeks estradiol and estrone rose rather than fell, and in 55 men aged 30 to 59 over 28 days estradiol rose 103 percent and dihydrotestosterone 71 percent while total testosterone did not move. Chrysin was one of several herbal ingredients in those products, so its own contribution cannot be separated out, but the change it was added to prevent happened anyway. The reason is pharmacokinetic. A single 400 mg oral dose produced peak plasma chrysin of only 3 to 16 ng/mL, with most of the dose recovered unchanged in the faeces, so the concentrations that inhibit aromatase in a dish are not reachable by swallowing a capsule.
Antioxidant and anti-inflammatory activity in cell culture only, never measured in people
Chrysin scavenges radicals and inhibits NF-kB in cell culture at micromolar concentrations. No human trial has measured an antioxidant or inflammatory outcome after oral chrysin. The size of that gap is the point: peak plasma chrysin after a single 400 mg oral dose was 3 to 16 ng/mL, roughly 0.01 to 0.06 micromolar, one to three orders of magnitude below the concentrations used in those cell experiments. Methylated analogues (5,7-dimethoxyflavone, 7-methoxyflavone, 7,4'-dimethoxyflavone) resist metabolism better, but that work is in cancer cell lines and rats, not people.
Given alongside irinotecan chemotherapy: a 20-patient safety pilot, not an efficacy result
The only study behind this is a pilot study of safety, not efficacy. Twenty patients with previously treated advanced colorectal cancer took chrysin twice daily for one week before and one week after each irinotecan infusion (350 mg/m2 every 3 weeks). There was no placebo group and no randomisation, so diarrhoea was never compared against a control arm and no prevention endpoint was met. No toxicity was attributed to chrysin, delayed diarrhoea was mild with 10 percent of patients reaching grade 3, and median loperamide use was 1 to 5 tablets per cycle. The plasma ratio of inactive to active irinotecan metabolite (SN-38G to SN-38) was essentially the same as in historical controls, so the proposed mechanism was not demonstrated in patients. Grade 3 or 4 neutropenia occurred in 25 percent. The authors concluded only that the combination may be safe and potentially useful and that this needs a randomised trial. This is a hospital oncology question, not a reason to buy chrysin: nobody on chemotherapy should add any supplement without their oncologist's agreement.
No anxiety evidence for chrysin itself: the calming data belong to whole passionflower
Chrysin is one constituent of Passiflora, and whole passionflower extracts have been tested in people for anxiety. Isolated chrysin has not. A PubMed search for chrysin combined with anxiety and restricted to human studies returns six records, none of which is a trial of chrysin in people. Crediting a whole plant's effect to one of its barely absorbed constituents is not evidence, particularly when passionflower also contains apigenin, alkaloids and GABA itself. If you want the passionflower data, buy passionflower.
Mechanism of action
Aromatase (CYP19A1) inhibition (in vitro only)
Chrysin binds and inhibits aromatase enzyme in cell-free assays and cell culture. Mechanism for theoretical estrogen reduction and testosterone preservation. Critical caveat: this in vitro mechanism does not manifest clinically with oral chrysin due to bioavailability problems. The mechanism explains the marketing but not the clinical reality.
Poor oral bioavailability — the central problem
Chrysin oral bioavailability is <1%, severely limiting systemic effects. Causes: (1) extensive first-pass intestinal metabolism by UGT1A1 (glucuronidation) and SULT1A1 (sulfation) — Caco-2 cell studies show rapid conjugation; (2) low aqueous solubility (<1 µg/mL) limiting dissolution; (3) P-glycoprotein efflux. Despite high in vitro potency, oral chrysin cannot achieve therapeutic plasma concentrations. This is the dominant pharmacokinetic reality.
Antioxidant via direct radical scavenging
C2-C3 double bond and 4-carbonyl provide hydrogen-donating capacity for radical scavenging. Mechanism for antioxidant activity in cell culture and limited animal contexts. Clinical relevance limited by same bioavailability constraints.
Local intestinal effects (where bioavailability not required)
Where chrysin can act locally without requiring systemic absorption — i.e., in the intestinal lumen — it shows potential clinical effects. The irinotecan work is the only case tested in people, and the mechanism stated here is the wrong way round. Chrysin upregulates UGT1A1 in Caco-2 intestinal cells, which would push the balance in the gut lining towards the inactive glucuronide SN-38G, rather than inhibiting beta-glucuronidase. In the one clinical pilot the plasma SN-38G to SN-38 ratio was no different from historical controls, so this mechanism has not been confirmed in patients and no gut-luminal indication has been proven.
Clinical trials
Controlled human study (Gambelunghe C, Rossi R, Sommavilla M, Ferranti C, Rossi R, Ciculi C, Gizzi S, Micheletti A, Rufini S, J Med Food 2003;6(4):387-90, doi:10.1089/109662003772519967).
Healthy male volunteers given daily propolis and honey containing chrysin for 21 days, with a separate control group. Urinary testosterone was measured at baseline and on days 7, 14 and 21 by GC/MS. Neither the number of volunteers nor the amount of chrysin delivered by the propolis and honey is available from the published abstract, so the exposure tested is unclear.
NO alterations in testosterone levels at any time point vs baseline or controls. Authors concluded: 'The use of these foods for 21 days at the doses usually taken as oral supplementation does not have effects on the equilibrium of testosterone in human males.' Fundamentally negative trial — the most cited evidence against chrysin's testosterone-boosting marketing claims.
Human pharmacokinetic study (Walle T, Otake Y, Brubaker JA, Walle UK, Halushka PV, Br J Clin Pharmacol 2001;51(2):143-6, doi:10.1111/j.1365-2125.2001.01317.x).
Seven healthy adult volunteers given a single oral 400 mg dose of chrysin, with chrysin and its metabolites measured in plasma, urine and faeces by HPLC.
Peak plasma chrysin was only 3 to 16 ng/mL, with an AUC of 5 to 193 ng/mL/h. Plasma chrysin sulphate ran about 30 times higher. Urine contained 0.2 to 3.1 mg of chrysin and 2 to 26 mg of chrysin glucuronide out of the 400 mg dose, and most of the dose came out in the faeces as unchanged chrysin. The authors concluded that oral chrysin has low bioavailability, mainly through extensive metabolism and efflux of metabolites back into the intestine. This is a pharmacokinetic measurement, not a health outcome: it tells you the capsule does not get in, not that it does anything once there.
Systematic review (Balam FH, Ahmadi ZS, Ghorbani A, Heliyon 2020;6(3):e03557, doi:10.1016/j.heliyon.2020.e03557).
Not a study in people. The review screened 1,721 records and included 20 articles on chrysin and aromatase: 17 in vitro, 2 in rats, and 1 in humans.
All but one of the 20 included studies found that chrysin inhibited aromatase, and the review's authors concluded that chrysin has aromatase-inhibiting potency. Read the denominator before the conclusion: that finding rests on 17 cell-culture studies and 2 rat studies. Only one included study was done in people, and it found no change in testosterone. The review did not conclude anything about oral bioavailability, and it did not show that a swallowed capsule lowers estrogen or raises testosterone in a person.